Survival and prognostic factors in BRCA1-associated breast cancer.
暂无分享,去创建一个
J. Klijn | H. Meijers-Heijboer | C. Seynaeve | M. Menke-Pluymers | M. Kriege | C. Brekelmans | A. V. van Geel | J. Blom | J. Klijn | H. Brüggenwirth | M. Tilanus-Linthorst | C. Bartels | C. Seynaeve | C. Brekelmans | A. Geel | C. Crepin
[1] L. V. van't Veer,et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers , 2005, British Journal of Cancer.
[2] W. Foulkes,et al. BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.
[3] H. D. de Koning,et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.
[4] J. Klijn,et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. , 2004, European journal of cancer.
[5] B. Haffty,et al. Conservative management of breast cancer in BRCA1/2 mutation carriers. , 2004, Clinical breast cancer.
[6] A. Troxel,et al. Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers , 2004, Annals of Surgical Oncology.
[7] J. Satagopan,et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.
[8] L. Bégin,et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1‐related breast carcinoma , 2003, Cancer.
[9] J. Klijn,et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. V. van't Veer,et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. , 2003, Cancer research.
[11] A. Vincent-Salomon,et al. Medullary breast carcinoma: prognostic implications of p53 expression. , 2003, The International journal of biological markers.
[12] L. Bégin,et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma , 2003, Cancer.
[13] A. Howell,et al. Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy , 2002, International journal of cancer.
[14] P. Chappuis,et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer , 2002, Journal of medical genetics.
[15] B. Ponder,et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. , 2002, Cancer research.
[16] G. Banna,et al. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. , 2001, Cancer treatment reviews.
[17] P. Kyyrönen,et al. Survival of breast cancer patients in BRCA1, BRCA2, and non‐BRCA1/2 breast cancer families: A relative survival analysis from Finland , 2001, International journal of cancer.
[18] A. Vincent-Salomon,et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] K. Phillips. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Bégin,et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] P. Chappuis,et al. The influence of familial and hereditary factors on the prognosis of breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] M. Stratton,et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.
[23] P. Oefner,et al. BRCA1‐related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics , 1998, International journal of cancer.
[24] D. Birnbaum,et al. Low frequency of lymph-node metastasis in BRCA1-associated breast cancer , 1998, The Lancet.
[25] C. Lewis,et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[26] D. Birnbaum,et al. Mutations at BRCA1: the medullary breast carcinoma revisited. , 1998, Cancer research.
[27] J. Ranstam,et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Klijn,et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.
[29] R. Gray,et al. Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Easton,et al. Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.
[31] L. Norton,et al. Appropriateness of breast‐conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2 , 2005, Cancer.
[32] U. Hamann,et al. Survival and tumor characteristics of German hereditary breast cancer patients , 2004, Breast Cancer Research and Treatment.
[33] S. Hilsenbeck,et al. Hazard rates of recurrence following diagnosis of primary breast cancer , 2004, Breast Cancer Research and Treatment.
[34] J. Klijn,et al. Rapid detection of BRCA1 mutations by the protein truncation test , 1995, Nature Genetics.